A pilot cross-sectional study to investigate the biomarker potential of phosphorylated neurofilament-H and immune mediators of disability in patients with 5 year relapsing-remitting multiple sclerosis

Abstract

Introduction: Multiple sclerosis is the most prevalent chronic autoimmune disease of the central nervous system with the first clinical symptoms typically appearing in early adulthood, and affecting over 2 million people worldwide (1). Relapsing-remitting multiple sclerosis (RRMS) is the current criteria-based most prevalent form of the three clinical presentations of multiple sclerosis (MS), relapsing-remitting, converted to secondary progressive, and primary progressive. It is characterized by neurologic worsening attacks or relapses followed by apparent recovery periods of masked progression of the disease...